RAPP Q1 2025 Earnings — Rapport Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

RAPPRapport Therapeutics, Inc. Common Stock

$1B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$27M

Net Income

-$24M

EPS (Diluted)

$-0.12

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$21M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$302M

Total Liabilities

$16M

Stockholders' Equity

$286M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$152,000	+100.0%
Operating Income	-$27M	-$17M	-58.6%
Net Income	-$24M	-$23M	-6.1%